US 12,252,540 B2
Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR)
Junming Yie, Warren, NJ (US); Donghui Shi, Thousand Oaks, CA (US); David J. Lloyd, Thousand Oaks, CA (US); Jinghong Wang, Palo Alto, CA (US); Glenn N. Sivits, Jr., Newbury Park, CA (US); Murielle M. Veniant-Ellison, Thousand Oaks, CA (US); Renee Komorowski, Ventura, CA (US); Neeraj Agrawal, Thousand Oaks, CA (US); Darren L. Bates, Oak Park, CA (US); Brandon C. P. Clavette, Coquitlam (CA); Ian N. Foltz, Burnaby (CA); Shu-yin Ho, Thousand Oaks, CA (US); Christopher Murawsky, Roberts Creek (CA); Xiaoshan Min, Burlingame, CA (US); and Zhulun Wang, Palo Alto, CA (US)
Assigned to Amgen Inc., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on May 27, 2021, as Appl. No. 17/332,578.
Application 17/332,578 is a division of application No. 16/285,118, filed on Feb. 25, 2019, granted, now 11,046,774.
Application 16/285,118 is a division of application No. 15/387,542, filed on Dec. 21, 2016, granted, now 10,294,303, issued on May 21, 2019.
Claims priority of provisional application 62/420,415, filed on Nov. 10, 2016.
Claims priority of provisional application 62/337,799, filed on May 17, 2016.
Claims priority of provisional application 62/387,486, filed on Dec. 23, 2015.
Prior Publication US 2022/0025059 A1, Jan. 27, 2022
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 38/17 (2006.01); A61K 38/26 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2869 (2013.01) [A61K 9/0019 (2013.01); A61K 38/1703 (2013.01); A61K 38/26 (2013.01); A61K 39/3955 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2299/00 (2013.01); C07K 2317/21 (2013.01); C07K 2317/32 (2013.01); C07K 2317/33 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/71 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 5 Claims
 
1. A nucleic acid molecule encoding an antibody selected from the group consisting of:
a) an antibody comprising a CDRL1, a CDRL2, a CDRL3, a CDRH1, a CDRH2, and a CDRH3, wherein said CDRL1 comprises SEQ ID NO: 702; said CDRL2 comprises SEQ ID NO: 859; said CDRL3 comprises SEQ ID NO: 1016; said CDRH1 comprises SEQ ID NO: 1173; said CDRH2 comprises SEQ ID NO: 1330; and said CDRH3 comprises SEQ ID NO: 1487;
b) an antibody comprising a light chain variable region comprising SEQ ID NO: 74 and a heavy chain variable region comprising SEQ ID NO: 231; and
c) an antibody comprising a light chain comprising SEQ ID NO: 388 and a heavy chain comprising SEQ ID NO: 545.